<DOC>
	<DOCNO>NCT01402063</DOCNO>
	<brief_summary>To obtain preliminary data randomize phase II study whether PPX/RT improve progression-free survival compare temozolomide/RT patient GBM without MGMT methylation .</brief_summary>
	<brief_title>PPX Concurrent Radiation Newly Diagnosed Glioblastoma Without MGMT Methylation</brief_title>
	<detailed_description>To evaluate toxicity PPX/RT To evaluate neuro-cognitive functional assessment patient GBM receive PPX/RT To obtain preliminary data randomize phase II study whether PPX/RT improve overall survival compare temozolomide /RT patient GBM without MGMT methylation facilitate planning phase III study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Histologically proven diagnosis glioblastoma gliosarcoma ( WHO grade IV ) GBM must unmethylated MGMT determine central laboratory Diagnosis GBM must make biopsy surgical excision , either partial complete ; long sufficient tissue determine MGMT status No prior chemotherapy radiation brain tumor Must able tolerate brain MRIs . *A diagnostic contrastenhanced MRI must perform postoperatively within 42 day prior study registration . KPS &gt; 60 . Age &gt; 18 Life expectancy least 3 month . Absolute neutrophil count &gt; 1500/mm3 , Platelets &gt; 100,000/mm , Creatinine &lt; 2 x ULN ALT AST &lt; 3 x upper limit normal ( ULN ) total bilirubin &lt; 1.5x ULN . Patients prior history low grade glioma receive prior radiation chemotherapy transformation grade IV brain tumor eligible . Women must nonlactating , surgically sterile , postmenopausal negative serum pregnancy test agree use adequate birth control . Males must agree use adequate birth control . Voluntary , sign informed consent . Acute infection medical condition would impair study treatment No active invasive malignancy unless disease free least 3 year . Prior temozolomide PPX . Prior use Gliadel wafer intratumoral intracavitary treatment permit . Prior radiotherapy head neck ( except T1 glottic cancer ) , result overlap radiation field . No diffuse leptomeningeal disease , gliomatosis cerebri . Use experimental chemotherapy drug within 60 day prior randomization trial . ( Use nonchemotherapy investigational agent must approve Brown University Oncology Group )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Brain Tumors</keyword>
	<keyword>Glioblastoma Multiforme</keyword>
	<keyword>GBM</keyword>
</DOC>